Kyverna Therapeutics Inc (KYTX) Stock Price, Quote & News

Company Profile

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; a...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 925 2492

Website: kyvernatx.com

Address:

5980 Horton Street, Suite 550, Emeryville, United States

Th3M4skedSt0nker Dec. 5 at 9:26 AM

$KYTX gonna make a nice Christmas gift. There will be one more very positive news catalyst before eoy and we will head into the new year with double digits.

0 · Reply

blocktrade Dec. 4 at 7:51 PM

$KYTX if this can finally break through that 8.45 high, I think it goes into double digits fast. Especially after the MS pump and target raise today.

0 · Reply

JarvisFlow Dec. 4 at 6:05 PM

Morgan Stanley updates rating for Kyverna Therapeutics ( $KYTX ) to Overweight, target set at 20 → 25.

1 · Reply

blocktrade Dec. 4 at 2:42 PM

$KYTX well let’s see if this bounce will hold. (Low volume)

1 · Reply

ZackInvest008 Dec. 1 at 9:01 PM

$KYTX

1 · Reply

blocktrade Dec. 1 at 8:59 PM

$KYTX getting tired of the way this trades.

1 · Reply

ZackInvest008 Dec. 1 at 8:59 PM

$KYTX Load zone again

1 · Reply

Kingcrab33333 Dec. 1 at 12:31 AM

$KYTX

0 · Reply

EliteTradingGoat Nov. 26 at 8:59 PM

$KYTX OOOUUTT +11%

0 · Reply

theBigDollarski Nov. 20 at 6:16 PM

$KYTX talk about a rug pull......

1 · Reply

Kyverna Therapeutics: Immune Reset Is Clinically Validated, Market Ignores Potential

Nov 12, 2025, 4:05 PM EST - 23 days ago

Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 8:00 AM EST - 25 days ago

Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 3, 2025, 8:00 AM EST - 4 weeks ago

Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance

Oct 29, 2025, 6:30 AM EDT - 5 weeks ago

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

Oct 25, 2025, 11:00 AM EDT - 5 weeks ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

Oct 22, 2025, 8:00 AM EDT - 6 weeks ago

Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis

Sep 24, 2025, 9:05 AM EDT - 2 months ago

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

Sep 15, 2025, 1:02 PM EDT - 2 months ago

Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025

Aug 28, 2025, 8:00 AM EDT - 3 months ago

Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event

Aug 25, 2025, 4:02 PM EDT - 3 months ago

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

Aug 20, 2025, 3:29 PM EDT - 3 months ago

Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026

Aug 12, 2025, 4:02 PM EDT - 4 months ago

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Jul 29, 2025, 8:30 AM EDT - 4 months ago

Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise

May 28, 2025, 4:02 PM EDT - 6 months ago

Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference

May 27, 2025, 3:42 PM EDT - 6 months ago

With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?

May 13, 2025, 4:02 PM EDT - 7 months ago

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Mar 27, 2025, 4:02 PM EDT - 9 months ago

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 21, 2025, 11:29 AM EDT - 9 months ago

Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025

Mar 3, 2025, 4:05 PM EST - 9 months ago

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Feb 7, 2025, 11:42 AM EST - 10 months ago

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Feb 6, 2025, 1:51 PM EST - 10 months ago

Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX

Feb 5, 2025, 11:54 AM EST - 10 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics

Feb 4, 2025, 3:51 AM EST - 10 months ago

Final Deadline for the Kyverna Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - KYTX

Jan 27, 2025, 3:22 PM EST - 11 months ago

KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Th3M4skedSt0nker Dec. 5 at 9:26 AM

$KYTX gonna make a nice Christmas gift. There will be one more very positive news catalyst before eoy and we will head into the new year with double digits.

0 · Reply

blocktrade Dec. 4 at 7:51 PM

$KYTX if this can finally break through that 8.45 high, I think it goes into double digits fast. Especially after the MS pump and target raise today.

0 · Reply

JarvisFlow Dec. 4 at 6:05 PM

Morgan Stanley updates rating for Kyverna Therapeutics ( $KYTX ) to Overweight, target set at 20 → 25.

1 · Reply

blocktrade Dec. 4 at 2:42 PM

$KYTX well let’s see if this bounce will hold. (Low volume)

1 · Reply

ZackInvest008 Dec. 1 at 9:01 PM

$KYTX

1 · Reply

blocktrade Dec. 1 at 8:59 PM

$KYTX getting tired of the way this trades.

1 · Reply

ZackInvest008 Dec. 1 at 8:59 PM

$KYTX Load zone again

1 · Reply

Kingcrab33333 Dec. 1 at 12:31 AM

$KYTX

0 · Reply

EliteTradingGoat Nov. 26 at 8:59 PM

$KYTX OOOUUTT +11%

0 · Reply

theBigDollarski Nov. 20 at 6:16 PM

$KYTX talk about a rug pull......

1 · Reply

Aawilliam2003 Nov. 19 at 6:56 PM

$KYTX trading like a stock that’s about to be acquired

2 · Reply

ZackInvest008 Nov. 19 at 6:39 PM

$KYTX Missed it by a week

1 · Reply

Aawilliam2003 Nov. 19 at 3:37 PM

$KYTX early 2026 target? $22

0 · Reply

Biotech_Beast Nov. 19 at 1:10 PM

$TGTX $KYTX Approval no later than Q1'27 for subcutaneous Briumvi is a pipe dream.

1 · Reply

Dirk1969 Nov. 18 at 7:59 PM

$KYTX @jacksparo still viewed ?

0 · Reply

blocktrade Nov. 18 at 7:57 PM

$KYTX new high coming

1 · Reply

blocktrade Nov. 18 at 4:56 PM

$KYTX volume!

0 · Reply

Biotech_Beast Nov. 18 at 11:18 AM

$TGTX I've had a look at where TG stands now, and $KYTX which has a competitor to TGTX's Azer-cel. https://seekingalpha.com/article/4844784-tg-therapeutics-positives-from-q325-earnings-but-competitors-progressing

1 · Reply

Ostrich91 Nov. 17 at 6:34 PM

$KYTX This is stock to buy now and rest. The MS treatment they are developing is revolutionary. It doubles the efficacy of the current standard of care. Finances are poor, but given the pipeline, it will be acquired, that’s good news

1 · Reply

hummer2277 Nov. 16 at 7:23 PM

$KYTX seeking alpha article with 55 price target. wow

0 · Reply

blocktrade Nov. 14 at 3:48 PM

$KYTX and there it is

1 · Reply

blocktrade Nov. 14 at 4:35 AM

$KYTX

0 · Reply

Market Cap	314.46M
Revenue (ttm)	0.00
Net Income (ttm)	-127.48M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	268,300
Avg Vol	728,336
Day's Range	N/A - N/A
Shares Out	43.80M
Stochastic %K	37%
Beta	3.66
Analysts	Strong Sell
Price Target	$24.00